BioCryst Pharmaceuticals | BCRX - سود قبل از مالیات





سود قبل از مالیات تغییر دادن تاریخ
Alnylam Pharmaceuticals USD 161.14M 77.83M 2025-12
BioCryst Pharmaceuticals USD 248.02M 235.89M 2025-12
Chugai Pharma JPY 169.9B 13.83B 2025-12
Daiichi Sankyo JPY 106.73B 48.96B 2025-12
DBV Technologies USD -33.16M 8.6M 2025-09
Enanta Pharmaceuticals USD -22.71M 95.08M 2024-12
Gilead Sciences USD 3.64B 1.21B 2025-09
GlaxoSmithKline GBP 1.23B 1.23B 2025-12
Glaxosmithkline GBP 2.46B 569M 2025-09
Incyte USD 389.94M 92.37M 2025-12
Ionis Pharmaceuticals USD -228M 99M 2025-12
Karyopharm Therapeutics USD -30.89M 1.16M 2024-12
Neurocrine Biosciences USD 239.4M 52.4M 2025-12
Novavax USD 17.9M 220.94M 2025-12
PTC Therapeutics USD -139.08M 116.01M 2025-12
Regeneron Pharmaceuticals USD 1.76B 244.6M 2025-09
Roche Holding CHF 4.79B 3.01B 2025-06
Sarepta Therapeutics USD -407.67M 213.63M 2025-12
Ultragenyx Pharmaceutical USD -128M 51.54M 2025-12
Vertex Pharmaceuticals USD 1.3B 15.8M 2025-09